Nektar Therapeutics (NASDAQ:NKTR) Shares Purchased by Meeder Asset Management Inc.

Share on StockTwits

Meeder Asset Management Inc. increased its stake in shares of Nektar Therapeutics (NASDAQ:NKTR) by 2,667.4% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 22,084 shares of the biopharmaceutical company’s stock after purchasing an additional 21,286 shares during the period. Meeder Asset Management Inc.’s holdings in Nektar Therapeutics were worth $786,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the stock. Crossmark Global Holdings Inc. raised its holdings in Nektar Therapeutics by 2.2% in the 2nd quarter. Crossmark Global Holdings Inc. now owns 14,244 shares of the biopharmaceutical company’s stock valued at $507,000 after acquiring an additional 301 shares during the last quarter. Northwestern Mutual Investment Management Company LLC raised its holdings in Nektar Therapeutics by 1.5% in the 1st quarter. Northwestern Mutual Investment Management Company LLC now owns 26,456 shares of the biopharmaceutical company’s stock valued at $889,000 after acquiring an additional 395 shares during the last quarter. TD Asset Management Inc. raised its holdings in Nektar Therapeutics by 0.5% in the 1st quarter. TD Asset Management Inc. now owns 84,241 shares of the biopharmaceutical company’s stock valued at $2,830,000 after acquiring an additional 427 shares during the last quarter. Mason Street Advisors LLC increased its holdings in shares of Nektar Therapeutics by 1.8% during the 1st quarter. Mason Street Advisors LLC now owns 24,838 shares of the biopharmaceutical company’s stock worth $835,000 after buying an additional 436 shares during the last quarter. Finally, Xact Kapitalforvaltning AB increased its holdings in shares of Nektar Therapeutics by 1.5% during the 2nd quarter. Xact Kapitalforvaltning AB now owns 31,980 shares of the biopharmaceutical company’s stock worth $1,138,000 after buying an additional 470 shares during the last quarter. Hedge funds and other institutional investors own 91.23% of the company’s stock.

Shares of Nektar Therapeutics stock opened at $17.01 on Thursday. The company has a fifty day moving average price of $28.62 and a 200 day moving average price of $33.70. The company has a current ratio of 14.09, a quick ratio of 13.97 and a debt-to-equity ratio of 0.22. Nektar Therapeutics has a twelve month low of $16.56 and a twelve month high of $69.76. The stock has a market cap of $3.13 billion, a price-to-earnings ratio of 4.50 and a beta of 2.67.

Nektar Therapeutics (NASDAQ:NKTR) last announced its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.17. Nektar Therapeutics had a negative net margin of 354.90% and a negative return on equity of 25.25%. The firm had revenue of $23.32 million during the quarter, compared to analysts’ expectations of $26.65 million. During the same period in the prior year, the company earned $5.33 EPS. The firm’s revenue was down 97.9% on a year-over-year basis. Analysts forecast that Nektar Therapeutics will post -2.93 earnings per share for the current year.

In related news, CFO Gil M. Labrucherie sold 25,000 shares of the company’s stock in a transaction on Monday, June 17th. The shares were sold at an average price of $33.71, for a total transaction of $842,750.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Jillian B. Thomsen sold 1,809 shares of the company’s stock in a transaction on Friday, August 16th. The stock was sold at an average price of $18.15, for a total transaction of $32,833.35. Following the sale, the senior vice president now directly owns 92,668 shares of the company’s stock, valued at $1,681,924.20. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 141,576 shares of company stock valued at $3,990,247. 4.02% of the stock is owned by corporate insiders.

NKTR has been the subject of a number of research analyst reports. Evercore ISI restated a “hold” rating and set a $37.00 price objective on shares of Nektar Therapeutics in a report on Sunday, August 11th. JPMorgan Chase & Co. downgraded Nektar Therapeutics from an “overweight” rating to a “neutral” rating and dropped their price objective for the stock from $62.00 to $33.00 in a report on Friday, August 9th. HC Wainwright restated a “hold” rating on shares of Nektar Therapeutics in a report on Tuesday, August 13th. ValuEngine upgraded Nektar Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 1st. Finally, BidaskClub downgraded Nektar Therapeutics from a “sell” rating to a “strong sell” rating in a report on Tuesday, July 16th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $49.15.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company develops NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and NKTR-214, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I to treat immuno-oncology.

Recommended Story: How Do Front-End Loads Impact an Investment?

Institutional Ownership by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Meeder Asset Management Inc. Reduces Position in Capri Holdings Ltd
Meeder Asset Management Inc. Reduces Position in Capri Holdings Ltd
Meeder Asset Management Inc. Buys 435 Shares of Allstate Corp
Meeder Asset Management Inc. Buys 435 Shares of Allstate Corp
Meeder Asset Management Inc. Reduces Stock Holdings in Helmerich & Payne, Inc.
Meeder Asset Management Inc. Reduces Stock Holdings in Helmerich & Payne, Inc.
SBA Communications Co.  Shares Sold by Meeder Asset Management Inc.
SBA Communications Co. Shares Sold by Meeder Asset Management Inc.
Cactus Inc  Position Increased by Meeder Asset Management Inc.
Cactus Inc Position Increased by Meeder Asset Management Inc.
Meeder Asset Management Inc. Purchases 622 Shares of Zions Bancorporation NA
Meeder Asset Management Inc. Purchases 622 Shares of Zions Bancorporation NA


© 2006-2019 Ticker Report